Why Johnson & Johnson Is Paying the Department of Justice Billions

From the smallest biotech to the biggest pharmaceutical stock The Motley Fool's Market Check-Up covers the health-care sector's biggest headlines, hottest market movers, and Obamacare's ongoing rollout.

In this segment, health-care analyst David Williamson discusses Johnson & Johnson's (NYSE: JNJ  ) massive $2.2 billion settlement with the Department of Justice, amid allegations that the company gave its sales representatives incentive to market the company's antipsychotic drug Risperdal for off-label sales. David looks at just how common these types of allegations and settlements are, and says that despite the worrying headlines, investors shouldn't be concerned.

Check out these dividend winners
Dividend stocks can make you rich. It's as simple as that. While they don't garner the notability of high-flying growth stocks, they're also less likely to crash and burn. And over the long term, the compounding effect of the quarterly payouts, as well as their growth, adds up faster than most investors imagine. With this in mind, our analysts sat down to identify the absolute best of the best when it comes to rock-solid dividend stocks, drawing up a list in this free report of nine that fit the bill. To discover the identities of these companies before the rest of the market catches on, you can download this valuable free report by simply clicking here now.


Read/Post Comments (1) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On November 11, 2013, at 9:53 AM, csabi wrote:

    While there is absolutely no justification for marketing off-label use of a drug, the so-called "kickbacks" paid to Omnicare is standard industry practice. Since the mid 90's when Managed Care organizations sprang up, pharmaceutical companies have been paying "Rebates" to these companies for "utilization" of their products. These ensure getting products on Formulary and serves as a guideline for Doctors to prescribe products to individuals based on their health insurance.

    Software companies have developed special programs to capture and process utilization data and rebates.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2720708, ~/Articles/ArticleHandler.aspx, 12/21/2014 10:17:35 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement